Advertisement
News
Subscribe to Drug Discovery & Development News

The Lead

Drug and Device Firms Paid $3.5B to Care Providers

October 1, 2014 | by Ricardo Alonso-Zaldivar | Comments

From research grants to travel junkets, drug and medical device companies paid doctors and leading hospitals billions of dollars last year, the government disclosed in a new effort to spotlight potential ethical conflicts in medicine. Read more...

TOPICS:
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

New Drug-Delivery Capsule May Replace Injections

October 1, 2014 4:15 pm | Comments

Researchers have devised a novel drug capsule coated with tiny needles that can inject drugs directly into the lining of the stomach after the capsule is swallowed. Read more...                      

TOPICS:

‘Stealth’ Nanoparticles Could Improve Cancer Vaccines

October 1, 2014 4:05 pm | Comments

Cancer vaccines have recently emerged as a promising approach for killing tumor cells before they spread. But so far, most clinical candidates haven’t worked that well. Now, scientists have developed a new way to deliver vaccines that successfully stifled tumor growth when tested in laboratory mice. Read more...

TOPICS:

Nine-Valent HPV Vaccine May Prevent Nearly 90% of Cervical Cancers

October 1, 2014 3:59 pm | Comments

Because nine human papillomavirus (HPV) subtypes were found to cause the majority of cervical precancers, a nine-valent HPV vaccine currently being investigated may be able to prevent more cervical cancers than current vaccines, according to new research. Read more...

TOPICS:
Advertisement

Merck Completes Sale of Consumer Unit to Bayer

October 1, 2014 3:52 pm | Comments

Drugmaker Merck said that it completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 billion. Read more...     

TOPICS:

Portola Pharmaceuticals Announces Phase 3 ANNEXA-A Data

October 1, 2014 3:45 pm | Comments

Portola Pharmaceuticals announced that its first Phase 3 study of andexanet alfa, a potential universal Factor Xa inhibitor antidote and U.S. Food and Drug Administration-designated breakthrough therapy, met its primary and secondary endpoints with high statistical significance. Read more...

TOPICS:

Ebola Treatment Makers Rise After First U.S. Case

October 1, 2014 3:29 pm | Comments

Shares of several drugmakers developing potential vaccines or treatments for the deadly Ebola virus rose in premarket trading, continuing a run that started after federal officials confirmed that the first case of the disease has been diagnosed in the United States. Read more... 

TOPICS:

Daiichi Sankyo Submits Cravit sNDA in Japan

October 1, 2014 12:57 pm | Comments

Daiichi Sankyo Co. Ltd. announced that it and its domestic generic subsidiary, Daiichi Sankyo Espha Co. Ltd., have submitted a supplemental New Drug Application (sNDA) in Japan for the synthetic broad-spectrum oral antibacterial agent Cravit Tablets. Read more...

TOPICS:

Have Our Bodies Held the Key to New Antibiotics All Along?

October 1, 2014 11:53 am | Comments

As the threat of antibiotic resistance grows, scientists are turning to the human body and the trillion or so bacteria that have colonized us— collectively called our microbiota— for new clues to fighting microbial infections. Read more...    

TOPICS:
Advertisement

Targeted Treatment Could Halt Womb Cancer Growth

October 1, 2014 10:06 am | Comments

A drug which targets a key gene fault could halt an aggressive womb cancer and shrink tumours, according to research published in the British Journal of Cancer. Read more...

TOPICS:

Early Antibiotic Use Linked to Childhood Obesity Risk

September 30, 2014 3:16 pm | Comments

The use of broad-spectrum antibiotics by children before the age of 24 months was associated with increased risk of obesity in early childhood. Read more...                         

TOPICS:

J&J Buying Alios for $1.75B

September 30, 2014 3:03 pm | Comments

Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion. Alios is a privately held company that focuses on developing therapies for viral diseases. Read more...         

TOPICS:

Scientists Engineer Antibiotics in Race Against Drug Resistance

September 30, 2014 2:56 pm | Comments

We face an urgent global health problem because scientists are not developing new antibiotics as fast as bacteria are developing antibiotic resistance. But new research from UCLA has made important progress toward solving this problem. Read more...

TOPICS:

Engineers Devise Technology for Rapidly Testing Drug-Delivery Vehicles

September 30, 2014 2:43 pm | Comments

Engineers have devised a way to rapidly test hundreds of different drug-delivery vehicles in living animals, making it easier to discover promising new ways to deliver a class of drugs called biologics, which includes antibodies, peptides, RNA, and DNA, to human patients. Read more...

TOPICS:

Testing Cancer Drugs' Benefit for Individual Patients

September 30, 2014 2:28 pm | Comments

An official at a life sciences startup based on a Purdue University innovation says his company may help oncologists see faster than ever which drug therapies will benefit cancer patients and to what extent. Read more...         

TOPICS:

Sanofi, Regeneron Announce Positive Dupilumab Results

September 30, 2014 11:00 am | Comments

Regeneron Pharmaceuticals and Sanofi announced that a Phase 2a study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading